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Abstract: Highly expressed in the enterohepatic system, pregnane X receptor (PXR, NR1I2) is a
well-characterized nuclear receptor (NR) that regulates the expression of genes in the liver and
intestines that encode key drug metabolizing enzymes and drug transporter proteins in mammals.
The net effect of PXR activation is to increase metabolism and clear drugs and xenobiotics from the
body, producing a protective effect and mediating clinically significant drug interaction in patients
on combination therapy. The complete understanding of PXR biology is thus important for the
development of safe and effective therapeutic strategies. Furthermore, PXR activation is now known
to specifically transrepress the inflammatory- and nutrient-signaling pathways of gene expression,
thereby providing a mechanism for linking these signaling pathways together with enzymatic drug
biotransformation pathways in the liver and intestines. Recent research efforts highlight numerous
post-translational modifications (PTMs) which significantly influence the biological function of PXR.
However, this thrust of research is still in its infancy. In the context of gene-environment interactions,
we present a review of the recent literature that implicates PXR PTMs in regulating its clinically
relevant biology. We also provide a discussion of how these PTMs likely interface with each other to
respond to extracellular cues to appropriately modify PXR activity.
Keywords: nuclear receptor; pregnane X receptor; xenobiotics; cell signaling; phosphorylation;
SUMOylation; ubiquitination; acetylation; PARylation
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1. Introduction

published maps and institutional affil-

Pregnane X receptor (NR1I2, PXR) is a liver- and intestine-enriched member of the
nuclear receptor (NR) superfamily of ligand-activated transcription factors. Based upon its
conserved DNA sequence homology with other previously identified NRs, several groups
cloned PXR in 1998 [1–4]. Subsequent combinatorial chemistry and high-throughput
screening approaches led to the discovery that structurally diverse steroids and a myriad
of clinically used pharmaceutical drugs activate this novel nuclear receptor superfamily
member. The PXR protein is now known as a master-regulator of drug-inducible gene
expression of an assemblage of functionally linked gene products in mammalian livers and
intestines. The knowledge that PXR activators all regulate the drug-inducible expression of
specific cytochrome P450 (CYP) enzymes and transmembrane drug transporter proteins
solved a years-old clinical observation in which administration of certain drugs induce
their own metabolism, and that of numerous other co-administered drugs in patients on
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combination therapy [5,6]. The CYP family of enzymes are monooxygenases involved
in the hydroxylation of steroids including corticosteroids, androgens, progestins, dehydroepiandrosterone, as well as foreign compounds including numerous xenobiotics and
clinically used drugs [7,8]. The first identified, and now canonical, PXR-target genes in the
liver were CYP3A4 and CYP2B6 [9–13]. The expression of the CYP3A4 gene in humans
is induced by a variety of compounds and drugs including xenobiotics, glucocorticoids,
anti-glucocorticoids (e.g., RU486, PCN), macrolide antibiotics (e.g., rifampicin), imidazole
antifungals (e.g., clotrimazole), HMG-CoA reductase inhibitors (e.g., lovastatin), and barbiturates (e.g., phenobarbital). More recently, data have emerged revealing that intestinal
epithelial cells are exposed to microbial-derived ligands derived from tryptophan and its
gut-specific microbial metabolite indole 3-propionic acid, which activate PXR to function
as a central regulator of the gastro-intestinal barrier function [14]. This regulation is intrinsically associated with intestinal bacteria involved with the metabolism of tryptophan and
the production of indoles such as indole 3-propionic acid that are known to activate PXR in
intestinal epithelial cells.
In general, the enzymes and transmembrane transporters that are up-regulated following PXR activation comprise a network of proteins that collaboratively function in the
oxidative metabolism and transport of numerous lipid-soluble xenobiotic and endobiotic
compounds, thereby converting these compounds into more water-soluble molecules for
eventual elimination from the body [15–18]. PXR was thus initially defined as a “xenosensor” that regulates a key protective response in our enterohepatic system [19]. On the
other hand, PXR activation represents the molecular mechanism of a class of clinically important drug–drug interactions in which one compound vastly accelerates the metabolism
of other pharmacotherapy in patients on certain combination therapies.
Outside of the liver, PXR has been shown to regulate P-glycoprotein in enterocytes
and other endothelial cell types involved in the gut–blood and blood–brain barriers [20–22].
PXR activation has also been implicated in the response to chemotherapy in reproductive
tissues such as ovaries [23–27]. This tissue distribution is in line with PXR’s role in xenobiotic and drug metabolism. Furthermore, the role of PXR as a nuclear receptor has evolved
to include its regulation of families of genes involved in steroid hormone homeostasis,
bile acid metabolism, oxidative stress, inflammation, cell proliferation, and glucose and
lipid metabolism [8,9,16,28–30]. More recent research efforts reveal that PXR influences the
expression of hundreds of genes, providing key evidence that PXR likely influences a wide
variety of cellular processes [31].
While it was initially believed that PXR exclusively resided in the nucleus where
it performed its role as a transcriptional regulator, it has since been shown that liganddependent translocation of PXR from the cytoplasm to the nucleus occurs [32,33]. In
the absence of ligand, PXR resides in the cytoplasm in a multi-protein complex with
CAR-cytoplasmic-retention-protein (CCRP) and heat shock protein 90 (HSP90) [33]. Upon
ligand binding, PXR undergoes a conformational change that promotes dissociation of the
cytoplasmic retention co-chaperone complex. Thus, PXR translocates to the nucleus where
it interfaces with its obligate partner, the retinoid acid X receptor-alpha (RXRα), to direct
genetic programs comprising a xenobiotic response of transactivation and transrepression
of both direct and indirect PXR-target genes, respectively.
The transactivation capacity of NR proteins is mediated by an exquisite and highly
choreographed interface with multi-protein enzyme complexes and scaffold proteins to alter post-translational modifications (PTMs) of chromatin-associated regulatory proteins [34].
Specific co-activator proteins that collaborate with PXR to modulate target-gene expression
include steroid receptor coactivator 1 (SRC1), SRC2, p300, and peroxisome proliferator activated receptor gamma coactivator 1 alpha (PGC1α) [3,4,35–38]. The co-repressor proteins
known to physically associate with PXR include the nuclear receptor co-repressor (NCoR)
and silencing mediator for retinoid and thyroid receptors (SMRT), histone deacetylase
3 (HDAC3), and SIRT1 [35,39–42]. In addition, several PTMs of PXR have been observed
or inferred that modulate PXR biological activity and sub-cellular location to include phos-
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The first direct line of evidence acquired that proved PXR is phosphorylated came from
Lichti et al. using a radiolabeling experimental approach [46]. This study further revealed
that modulation of threonine phosphorylation was achieved by cyclic AMP through PKA
signaling pathways. It is noteworthy that PKA signaling interfaced very differently with
PXR transactivation capacity in both rat and human liver cells, when compared with
those from mice [47]. Increased PKA activity caused synergistic increases in Cyp3a11 gene
expression by PXR activation in cultured mouse hepatocytes. Conversely, increased PKA
signaling produced robust decreases in PXR-mediated induction of Cyp3A1 and CYP3A4
gene expression in rat and human hepatocytes, respectively. Moreover, these authors
discovered that PKA signaling produces an increased strength of association between PXR
and the NCoR in cell-based assays, which may explain the strong repression in CYP3A
gene expression in rats and humans when compared with mice. The biological significance
of the polar opposite effects of PKA signaling in mice when compared with humans and
rats is not well understood, although this remains a clear and rather unique observation.
This is a potent reminder that rats are not humans, and humans are not mice with respect
to their biology, per se.
A systematic analysis of predicted phosphorylation sites within the human PXR
protein led researchers to hypothesize that multiple serine and threonine residues could
potentially be impacted by kinase phosphorylation events on the PXR protein [46]. The
authors used site-directed mutagenesis to study eighteen different predicted sites of serine
(Ser) and threonine (Thr) phosphorylation. This study revealed that Ser-8, Thr-57, Ser-208,
Ser-305, Ser-350, and Thr-408 were predicted to potentially have biochemical relevance in
the regulation of PXR biology. It is now well established that phosphorylation of human
PXR by PKC or PKA is associated with decreased transcription of its target genes in cellbased assays. Studies by Pondugula et al. have inferred a role for phosphorylation of
Thr-57 by p70 S6 kinase to potentially regulate its DNA-binding activity [48]. Additional
mutagenesis studies infer that PXR phosphorylation at Thr-248 and Thr-422 plays a role in
modulating the ligand-mediated transactivation function of PXR [61].
More recent studies using direct methods to identify sites of phosphorylation have
uncovered the specific regulatory roles of numerous protein kinases in the regulation of
PXR biology. For instance, using a novel phospho-peptide antibody and Western blot
analysis, Gotoh et al. showed that the Ser-350 residue of PXR was phosphorylated by
VRK1, a member of the vaccinia-related kinase (VRK) family of serine/threonine protein
kinases, in hepatocytes in conditions of low glucose. Recent studies have unveiled how
phosphorylation of PXR at Ser-350 by VRK1 served as a molecular signal for increased
hepatic gluconeogenesis and perhaps drug-mediated impairment of glucose tolerance in
humans through activation of PXR [62–64]. The VRK1 protein has previously been shown
to promote the stability and nuclear accumulation of a transcriptionally active p53 molecule
and, in vitro, to phosphorylate Thr-18 of p53 and reduce p53 ubiquitination [65], providing
a plausible paradigm for this important nuclear kinase in the regulation of PXR biology in
response to glucose signaling.
An important recent research effort mechanistically linked PXR phosphorylation at
amino acids Thr-135 and Ser-221 to co-regulatory protein-binding specificity. Using a novel
adenovirus-mediated recombinant PXR expression, purification, and recovery system
coupled with mass spectrometry, Cui et al. demonstrated that human PXR, directly recovered from cultured primary hepatocytes, was phosphorylated at Thr-135 and Ser-221 [66].
Phospho-mimetic mutation at Ser-221 (S221D) switched PXR corepressor protein partner
preference from SMRT to NCoR. Moreover, the phospho-mimetic mutation at Ser-221
decreased the strength of interaction between PXR and transcription co-regulatory proteins
RXRα, SRC1, SRC2, and PBP [66]. Studies by Elias et al. also directly identified Thr-135,
among several other sites of phosphorylation, in cell-based assays using mass spectrometry [67]. Studies by Sugatani et al. revealed that phosphorylation of PXR at Thr-290
regulates the nuclear translocation of human PXR by Ca2+/calmodulin-dependent protein
kinase II [51]. This same group has produced a more recent study which suggested that
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the degradation of human PXR is regulated through phosphorylation by PKC at Thr-408
to enter the CHIP/chaperone-dependent stability check and the cytoplasmic autophagy
degradation pathway [68].
Taken together, these observations delineate that the response of PXR to modulation of its phosphorylation status can determine its biological function and suggest that
further investigation is warranted to more fully understand the regulation of PXR by
phosphorylation. Unlike the earliest studies of PXR phosphorylation, which relied heavily
upon in silico phosphorylation prediction analysis of inferred consensus phosphorylation
sites, more fruitful studies of this important NR family member should likely be accomplished using techniques that allow for the direct observation of PXR PTMs, such as mass
spectrometry-based approaches, to substantially move the field forward.
2.2. SUMOylation
SUMOylation is a post-translational modification involved in the regulation of various pivotal biochemical processes that include nuclear-cytosolic transport, transcriptional
regulation, apoptosis, protein stability, response to stress, and progression through the cell
cycle [69]. Four small (approximately 11 kilodalton) SUMO proteins (originally termed sentrins) have been identified, which are termed SUMO1, SUMO2, SUMO3, and SUMO4 [69].
The structures of SUMO2 and SUMO3 are 97% homologous to each other. Hence, these
two SUMO family members are often termed SUMO2/3 in the literature, and in fact have
very similar biochemical function in many cell-based and in vivo biochemical assays. In
contrast, SUMO1 is 45% homologous to SUMO2/3 and is therefore thought of as being
functionally distinct from SUMO2/3. As with ubiquitination, SUMOylation pathways
involve a cascade of enzymatic reactions which culminate in the attachment of a small
ubiquitin-like modifier (SUMO) on key lysine (Lys) residues in its target substrate proteins.
Target protein Lys residues can be modified by a single SUMO moiety, typically by SUMO1,
or similar to ubiquitin, can form chains through an internal SUMOylation event on Lys-11
within SUMO2/3 on certain substrate proteins. Moreover, SUMO can be ubiquitinated
to form mixed SUMO-ubiquitin chains. While the process of SUMOylation has many
similarities with the ubiquitination process, the SUMO enzymatic cascade is distinct from
the cascade responsible for ubiquitination.
The SUMOylation pathway starts with the heterodimeric E1 SUMO-activating enzyme (SAE1/SAE2). The activated SUMO molecule is then transferred to the E2 SUMOconjugating enzyme (Ubc9). The E3 SUMO-ligase enzymes then engage with their respective target substrate proteins to complete the SUMOylation process [70,71]. In mammals,
four SUMO E3-ligase genes in the protein inhibitor of activated STAT (PIAS) genes exist: PIAS1, PIAS2 (also known as PIASx), PIAS3, and PIAS4 (also known as PIASy) [72].
Very similar to the ubiquitination process, the SUMOylation cycle includes maturation of
pre-SUMO protein through a proteolytic process that involves cleavage at its C-terminus
by a family of sentrin proteases (SENPs), followed by activation through thioester bond
formation, conjugation, ligation and de-modification by SENPs. There are six dedicated
SUMO-specific members of the SENP family to include: SENP1, SENP2, SENP3, SENP5,
SENP6, and SENP7 [73]. The family of SENPs are dual function proteases that both activate pre-SUMO, as well as detach SUMO moieties from SUMOylated target proteins in a
SENP-specific manner.
Initial studies of PXR SUMOylation using in vitro methods revealed that human PXR
could indeed serve as a substrate for SUMO1, SUMO2, or SUMO3 [74]. Cell-based analysis
using cultured HeLa cells revealed that PXR was preferentially modified by the SUMO3
protein to form robust SUMO chains. To understand where the SUMOylation occurred
on the PXR protein, experiments from two different research groups suggest that both
K108 and K128/K129 serve as the principal SUMO attachment sites [56,58]. Additional
cell-based experiments into the enzymatic cascade by Cui et al. revealed that PIAS1 and
PIAS4 can both function as the most effective SUMO-E3 ligase enzymes for driving the
SUMOylation of PXR, while SENP2 is the most effective de-SUMOylating SENP enzyme
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Figure 2. PXR is ubiquitinated in cells. The plasmid encoding 6x-Histidine-tagged PXR (His-PXR)
protein was transfected alone or together with an expression vector encoding ubiquitin (Ub) into
HeLa cells. Twenty-four (24) hours post-transfection, cells were treated for an additional 24 h (VEH
= 0.1% DMSO, Rif = 10 µM, MG132 = 25 µM). Total cell extract was subjected to purification using
nickel-linked agarose beads, followed by SDS-PAGE and subsequent Western blotting with anti-PXR
antibodies (Santa Cruz-H11).
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Multiple E3 ubiquitin ligase enzymes have been identified that appear to drive the
ubiquitination of PXR. In 2012, a yeast two-hybrid screen identified RANBP2-type and C3HC4type zinc finger-containing 1 (RBCK1, also known as HOIL-1L) as a likely E3-ubiquitin ligase
and PXR-binding protein [54]. The RBCK1 gene encodes a 58 kDa protein comprised of an Nterminal ubiquitin-like (UBL) domain, an Npl4-type zinc finger (NZF) domain, and a catalytic
C-terminal RBR domain known as ring-B-box-coiled coil 1. It is noteworthy that RBCK1, in
addition to binding and regulating PXR ubiquitination, also regulates NF-кB activity through
its interface with the NF-кB essential modulator (NEMO) [77]. A 2014 study using a small
interfering RNA (siRNA)-based screen of human kinases coupled with mass spectrometry
analysis identified the ubiquitin protein ligase E3 component n-recognin 5 (UBR5) as another
likely PXR-targeted E3 ubiquitin ligase [78]. Furthermore, this study revealed that the dual
specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) negatively regulates human
PXR stability and activity. In their model, the phosphorylation of PXR by DYRK2 facilitates
the ubiquitination of PXR by UBR5 through the formation of a multi-protein complex to
regulate PXR homeostasis. These findings provide an additional mechanism whereby human
PXR stability is regulated by kinase signaling-dependent ubiquitination of PXR.
The accepted canonical signal for proteasomal recognition is a poly-ubiquitin chain that is
anchored to a Lys residue in the target substrate, and is assembled through isopeptide bonds
involving Lys-48 (K48) of ubiquitin [79]. In previously unpublished data, we show here that the
signal-dependent poly-ubiquitination of PXR via K48-linked chain formation on ubiquitin is
stimulated by a constitutively active form of mitogen activated protein kinase kinase kinase
(MEKK1) (a.a. 380–672) (Figure 3). These data are significant in that the MEKK signaling
pathway links inflammation to NF-кB transcription, providing a plausible central molecular
mechanism for the interface between drug metabolism (PXR) and the inflammatory signaling
pathway (NF-кB) in the liver and intestines. In conclusion, PXR is able to be ubiquitinated at
specific Lys residues to include Lys-109, Lys-150, and Lys-170. To summarize, the E3 ubiquitin
ligases that have been identified to interact with PXR include UBR5, RBCK1, and TRIM-21. The
ubiquitination of PXR is inextricably influenced by other PTMs such as phosphorylation, ADPribosylation, and SUMOylation. Taken together, these studies indicate that the ubiquitination
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2.4. Acetylation
Protein acetylation is one of the major PTMs in eukaryotic organisms, in which the
acetyl group from acetyl coenzyme A (Ac-CoA) is attached to a specific site on a newly
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2.4. Acetylation
Protein acetylation is one of the major PTMs in eukaryotic organisms, in which the
acetyl group from acetyl coenzyme A (Ac-CoA) is attached to a specific site on a newly
formed polypeptide chain. In humans, it has been speculated that 80–90% of all proteins
become co-translationally acetylated at their N-termini [80]. Another distinct type of protein
acetylation targets the epsilon-amino group of Lys residues in specific target proteins [81].
Initially characterized in histone proteins, it was speculated that acetylated-Lys residues
were heavily involved in regulating gene activation; thus, the family of enzymes catalyzing
Lys acetylation were termed histone acetyltransferases. Nevertheless, Lys-acetylation is not
exclusively limited to histone proteins, and the enzymes that catalyze protein acetylation
have been renamed lysine-acetyltransferases (KATs) [82]. A large family of KATs has
been identified that function to attach acetyl groups to Lys residues on specific subsets of
target proteins [83]. Likewise, histone-deacetylase enzymes are now referred to as lysinedeacetylases (KDACs) to more accurately describe their function of removing acetylation
on numerous non-histone proteins, to include many transcription factors. The KDAC
superfamily of proteins is grouped into four separate classes based on their function and
DNA sequence similarity. Class I, II, and IV are considered “classical” HDACs whose
activity can be pharmacologically inhibited in cells by trichostatin A (TSA). Class I, II,
and IV also possess a zinc-dependent active catalytic site. The class III KDAC enzymes
comprise a distinct sub-family of NAD+ -dependent proteins known as sirtuins. Sirtuins
are unique in that they are totally unaffected by treatment with TSA [84].
A recent study suggests that alterations in the acetylation status of the PXR protein has
a profound effect on its transactivation capacity. Biswas et al. revealed that PXR is directly
acetylated in a transfected cell line [85]. Ligand-mediated activation of PXR reduces the
levels of acetylation, and the deacetylation of PXR is mediated, at least partially, by a
class III NAD+ -dependent KDAC called SIRT1. Another study from this group identified
p300, well-known for its ability to deacetylate numerous NRs, as a likely KDAC enzyme
that removes acetyl groups from Lys residues within PXR [86]. Moreover, ligand-induced
activation of a PXR expression vector containing an acetyl-mimetic mutation at the Lys-109
position (K109Q) reduced levels of PXR-transactivation capacity in response to treatment
with SR12813, a well-known human PXR activator. The p300 KAT enzyme regulates
transcription by directly binding to NRs through a well-defined NR-interaction domain
(NRID) [87].
Additional insights into the role of PXR acetylation revealed that pharmacological
inhibition of PXR deacetylation with TSA reduced the induction of PXR-target genes [57].
In addition, this study revealed an acetylation-dependent multi-protein complex comprised
of PXR, SMRT, and HDAC3, a well-defined NR co-repressor complex. Of note, the study
by Cui et al. also revealed a reciprocal effect of PXR SUMOylation and acetylation.
In another study, Bakshi et al. revealed that PXR is also acetylated on Lys-170 by KAT5,
a well- known KAT protein (also called TIP60), that is involved in regulating chromatin
remodeling, transcription, and other nuclear processes by acetylating histone and nonhistone proteins. In this study, it was revealed that KAT5 utilizes its NR-box to interact
with the LBD region of PXR and acetylates PXR at Lys-170 to induce its intra-nuclear
reorganization [88]. Interestingly, these authors observed that PXR interaction with TIP60
augments the catalytic activity of TIP60 towards the acetylation of histone proteins. It is
therefore abundantly clear that the acetylation of PXR plays a key role in defining PXR
transactivation capacity and altering its biological function.
PXR has been shown to have a role in major metabolic processes within the body, including lipid metabolism, drug metabolism, and gluconeogenesis [66,89,90]. Furthermore,
nutrient excess conditions have been shown to promote acetylation levels of metabolic regulators, including NR proteins specifically, which may suggest the physiological relevance
of PXR acetylation in patients with obesity and other metabolic disease processes. Further
research efforts should be focused on gaining insight into the role of interplay between
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PXR acetylation and chronic metabolic disease pathologies and linking that to possible
therapeutic approaches.
2.5. Poly(ADP-Ribosyl)ation
Poly(ADP-ribosyl)ation, also known as PARylation, is a PTM in which polymers of
ADP-ribose (poly(adenosine diphosphate-ribose)) are covalently attached to proteins by
PAR polymerase (PARP) enzymes in the ADP-ribosyltransferase (ART) superfamily [89].
ADP-ribosylation is characterized by the addition of ADP-ribose from NAD+ . Poly(ADPribosyl)ation has classically been studied in immediate DNA-damage-dependent PTMs of
histones and other nuclear proteins that contribute to the survival of injured proliferating
cells. In a signal-dependent manner, the polymerase enzymes covalently attach poly(ADPribose) polymers to themselves and appropriate acceptor proteins to include histones
and other DNA-binding proteins. ADP-ribosylation is best characterized to regulate
chromatin organization, DNA repair, transcription, replication, and other biochemical
processes. The role of PTM via ADP-ribosylation has been established in DNA damage
signals, DNA double-stranded breaks in response to cellular toxicity, the regulation of cell
cycle checkpoints, and apoptosis pathways. Notably, the addition of ADP-ribose is not a
discrete event; rather, it is part of a symbiotic and combinatorial relationship between posttranslational modifiers and its effects have yet to be fully elucidated. The PARP enzymes
have been more extensively studied within the ART superfamily and are best studied in
PARP-1. The PARP-1 protein is implicated in the transcriptional activity of NF-kB and its
subsequent downstream inflammatory effectors [90]. The relationship between PARP-1
and NF-kB was first studied in the context of septic shock. PARP-1 deficient mice were
exposed to the bacterial component lipopolysaccharide (LPS), a known inducer of NF-kB
transcriptional activity. Due to LPS, the PARP-1 null mice were found to be resistant to
septic inflammatory cascade associated with NF-kB, suggesting that PARP-1 plays a role in
inducing NF-kB [90]. In contrast to NF-kB activity modulation, ADP-ribosylation of PXR is
not currently as well characterized in the literature; however, a key interface between drug
metabolism and inflammation is well-known [91–95].
Poly(ADP-ribosyl)ation of PXR has been solely explored by Wang et al. [59]. The regulation of acetaminophen (APAP) metabolism and toxicity by PXR activation is well studied,
and therefore provides good scaffolding to explore the effects of ADP-ribosylation [96].
N-acetyl-p-benzoquinone imine (NAPQI), also known as NAPBQI, is a toxic byproduct
produced during the CYP3A-mediated xenobiotic metabolism of the analgesic paracetamol
(acetaminophen). Using a mouse model, Wang et al. revealed that PARP-1 was responsible
for ADP-ribosylation of PXR in the context of PXR-activators to increase APAP metabolism.
PARP-1 was activated in the presence of APAP and subsequently ADP-ribosylated PXR.
ADP-ribosylated PXR up-regulates Cyp3a11 gene expression, thereby increasing APAP hepatotoxicity via increased metabolism to NAPQI. The interaction between PXR and PARP-1
was found to be within the BRCA-C terminus at the auto-modification domain of PARP-1
and the ligand-binding domain (LBD) of PXR. The PXR-LBD is where ADP-ribosylation
occurred [3]. The finding that activation of PXR causes up-regulation of Cyp3a11 mRNA
and a subsequent increase in sensitivity to hepatotoxicity is congruent with prior studies [96,97]. However, PXR (−/−) mice have been reported to have a 3-to-4-fold greater
expression of Cyp3a11, yet decreased sensitivity for hepatotoxicity, suggesting that the role
of PXR on cytochrome P450 induction is complex and accessory protein cofactor crosstalk
is present [16,97].
The role of ADP-ribosylation in the regulatory networks of PXR and NF-kB activation is stunning and clinically important. The strong inverse relationship between drug
metabolism pathways and the inflammatory response suggests an interesting and important interconnected regulatory mechanism involving ADP-ribosylation that needs to be
better characterized and studied [98]. This interconnection likely involves coordination
with different PTMs as reported in other cellular processes [99]. A scheme representing the
PXR protein and its associated PTMs are annotated with the respective studies in Figure 4.
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responded to, in order to safeguard our bodies’ needed biochemical, nutritional, inflammatory, and pharmacological homeostasis. The molecular choreography that is activated
following xenobiotic, inflammatory, and nutritional stress relies heavily on PTMs. Protein
modifications with ubiquitin and the small ubiquitin-like modifier SUMO have recently
emerged as important regulatory means to inversely coordinate inflammation and drug
metabolism pathways. In addition, chains of ubiquitin, SUMO, and PAR all contribute
to the assembly of multi-protein complexes found at genomic PXR-binding sites of druginducible gene expression in the liver and intestines through alterations in PXR PTM status
in order to regulate specific temporal and spatial aspects of PXR-mediated gene activation.
Here, we review recent advancements in our understanding of how phosphorylation, ubiquitylation, SUMOylation, and PARylation coordinate the xenobiotic response and highlight
emerging examples of an intricate interplay between these chain-like modifications during
the cellular response to potentially toxic environmental stress.
3.1. PXR and SUMOylation
It has been widely held that SUMOylation of different transcription factors leads
to transcriptional repression [100]. The current knowledge paradigm of transcriptional
suppression holds that SUMOylation results in the recruitment of histone deacetylase
enzymatic activity to target promoters. In particular, HDACs are thought to be recruited to
these promoters following SUMOylation through novel protein–protein interactions. This
recruitment leads to increased histone deacetylation, and hence, transcriptional repression
at NR-specific target genes. This paradigm suggests an important integration point for
two protein-modifying pathways in the cell, the SUMO and deacetylation pathways, that
combine to promote transcriptional repression. Cui et al. observed that the introduction of human PXR along with PIAS1, an E3 SUMO-protein ligase, into PXR-KO mouse
hepatocytes significantly increased the ligand-inducible transactivation of Cyp3a11 gene

Cells 2021, 10, 3262

11 of 19

expression, when compared to transduction with human PXR alone [56]. Priyanka et al.
observed similar results when they found that transfection of the HepG2 cell line with
SUMO1 significantly enhanced the transcriptional activity of PXR towards rifampicinmediated induction of CYP3A4 in a dose-dependent manner. In contrast, using modified
PXR-SUMO fusion protein expression vectors that directly fuse SUMO1 or SUMO3 to PXR
indicate that this form of linear SUMO-PXR fusion protein produces a strong repression
of its transactivation capacity in reporter gene analysis [57]. The covalent attachment of
SUMO to the N- or C-terminus of PXR examines the direct effect of SUMO-modified PXR,
when compared to the natural isopeptide linkage that occurs when PXR is SUMOylated
through the normal endogenous enzymatic cascade stimulated SUMOylation by directly
increasing levels of PIAS1, PIASy, SUMO1, and SUMO3, respectively [56,58,101]. In addition to increased SUMOylated PXR, the SUMOylation of many co-regulatory proteins
is also likely to be increased in these experiments. Future efforts should focus on the
differential effects of PXR SUMOylation upon direct PXR-target gene expression versus
trans-repression of inflammatory response genes to elucidate molecular mechanisms of
these two important intertwined pathways.
3.2. A SUMO-Acetyl Switch
A direct correlation was noted between PIASy-driven SUMO(1)ylation of PXR and
levels of ubiquitinated PXR, suggesting that SUMO-modification of PXR increases ubiquitylation, and likely mixed SUMO-ubiquitin chain formation. Importantly, both the
acetylation and SUMOylation status of the PXR protein affect its ability to associate with the
KDAC3/HDAC3 in a complex with the SMRT corepressor protein. Co-immunoprecipitation
of PXR together with KDAC3 is abolished following PXR SUMO(3)ylation by PIAS1. However, inhibition of PXR deacetylation with TSA restores the interaction with HDAC3 in
the face of PIAS1 and SUMO3 [57]. These data suggest that the PXR-co-repressor multiprotein complex is acetylated and poised for gene activation, forming a “gene-off” posture.
The acetylation of PXR marks this NR protein as “competent” to become SUMOylated to
thereby drive SUMO-PXR-dependent transrepression processes through protein–protein
interactions with other transcriptional machinery, or to form ubiquitin-PXR to drive a
round of canonical PXR-target gene expression. Overall, the data support a model in which
a SUMO-acetyl switch occurs such that acetylation likely marks PXR as competent to fire a
round of transcription, or to acquire SUMO-modification to drive transrepression of NF-кB
target gene expression, likely through SUMO-dependent processes.
3.3. PXR, Phosphorylation, and Drug Metabolism
A recent study indicates that PXR activation inhibits platelet function, and that effect
is associated with the inhibition of the Src-family of kinase enzymes, strikingly, in the
absence of a nucleus [102]. This study therefore has identified rapid and non-genomic
regulatory effects of PXR activation on basic platelet function and subsequent thrombus
formation. We suggest that PXR activation with agonists in platelets could provide additional cardio-protective benefits for heart attack patients by preventing inappropriate
thrombus formation. It is theoretically possible that PXR activation can be achieved outside
of the ligand-dependent manner described here, though it has yet to be demonstrated for
this pivotal NR family member whether all PXR activation is ligand-dependent, or is a
response to phosphorylation, per se.
Both the PKA- and PKC-signaling pathways have been definitively shown to reduce
CYP3A gene expression in hepatocytes when active. However, it is still largely unknown if
they do so through phosphorylation of PXR and their total target sites of phosphorylation
on the PXR protein. It is abundantly clear that there are numerous sites of phosphorylation
on PXR, and the regulation of PXR biology is thought to involve its phospho-modification
at multiple sites through numerous signaling pathways.
It is of note that important pro-inflammatory cytokines including interleukin-1, interleukin-6,
and TNFα can activate PKC signaling, suggesting a direct and suppressive effect of PXR and
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its target genes during inflammatory conditions. It is also important to note that hepatocyte
growth factor decreases PXR expression, meaning during periods of liver regeneration CYP
expression will be decreased. Increased levels of CDK2 also produce a decrease in CYP3A4
and CYP2B6 gene expression in human hepatocytes. Taken together, CYP expression and
drug metabolism are reduced during inflammation and the primary mechanism through
which PXR activity is repressed is through its phosphorylation [103].
3.4. PXR and Glucose Metabolism
There are many physiological associations that PXR phosphorylation has in conjunction with chronic metabolic diseases. PXR activation will enhance glucose levels in the
body, both directly and indirectly. It has been shown that statin-activated PXR caused
depressing effects on SGK2, a gluconeogenesis gene repressor [102]. Activated PXR is
effectively repressing a repressor of gluconeogenic genes. In addition, activated PXR also
interacts with the FOXO1 gene, decreasing the expression of the insulin receptor substrate
gene (IRS), decreasing insulin receptor signaling [104]. It is important to note that PXR
is working in tandem with another nuclear receptor, the constitutive androgen receptor
(CAR), to decrease IRS expression. Therefore, activated PXR can have an impact on serum
glucose levels and is thus implied in glucose-associated metabolic diseases, such as type 2
diabetes mellitus. Further research and data are needed in this area of glucose-associated
diseases and PXR. However, through understanding the inhibitory effects of phosphorylation on PXR, there could be avenues of exploration in the prevention and treatment of
these diseases through this mechanism.
3.5. PXR and Lipid Metabolism
Molecular analysis of PXR’s effects on lipid metabolism shows that Rif-PXR activates
the SLC13A5 gene, which will translate a transport protein that allows citrate, a fatty acid
precursor, into the mitochondria of human hepatocytes [105]. Excess activation could
possibly lead to the accumulation of too much citrate and consequently accumulated fatty
acids. Therefore, it is hypothesized that PXR activation plays a role in lipid storage diseases,
such as hepatic steatosis. It is unclear the impact PXR activation plays in hepatic steatosis,
but it is theorized that the phosphorylation of PXR could negatively contribute to the
accumulation of lipid in liver tissue.
3.6. PXR and Inflammation
The interplay between PXR and NF-кB has been well described in the literature
[74,91,98,106–113]. The balance between these two proteins allows for negative crosstalk
between drug metabolism and inflammation. During inflammatory conditions, PXRtarget gene expression is remarkably decreased. Conversely, PXR activation produces a
repression of inflammatory genes. This phenomenon can be exploited to treat inflammatory
conditions, most historically inflammatory bowel disease [95,96,114,115]. A further thrust
of research is needed in this field in order to fully elucidate the molecular mechanisms of
this phenomenon; however, SUMOylation of PXR and its heterodimeric partner RXRα’s
ability to interact with NF-кB undoubtedly play a role.
3.7. PXR and Cancer
Clinically, much is still left to be uncovered concerning the effects PTMs have on PXR
influenced drug–drug interactions. Because PXR is a direct substrate for phosphorylation
by CDK2 the use of potential therapeutic cyclin-dependent kinase inhibitors is expected to
cause a significant decrease in CYP3A4 and P-glycoprotein [62,63,102]. This fact suggests
that the adverse effects associated with cancer pharmacotherapy using cyclin-dependent
kinase inhibitors are related to PXR biology. Given the vast number of kinases associated
with the phosphorylation of PXR, additional research is required to understand the precise
molecular mechanisms behind each. Essential kinases, such as CDK2, are well understood
to this point as elucidated in this theme issue. However, a greater understanding of many
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others is required to help formulate better dosing regimens for many promising drugs for
treating metabolic issues, inflammatory issues, and cancers.
In the context of certain types of cancer, PXR activation regulates cell proliferation,
metastasis, apoptosis, anti-apoptosis, inflammation, and oxidative stress differentially depending on cancer cell-types that include prostate, breast, ovarian, endometrial, and colon
cancer [116]. PXR activation also induces differentiation of osteoblasts and apoptosis of
osteoclasts and certain leukemia cells [114,115,117–119]. These studies indicate that control
of cell proliferation and cell differentiation following PXR activation is very likely tissueand cell-type specific. A similar theme plays out in cancer cells in which PXR differentially
regulates cell growth through multiple mechanisms in a variety of cancers that include
liver, prostate, breast, ovarian, endometrial, cervical, and colon. Additionally, PXR is
involved in regulating the metastatic phenotype of various cancer cells [120–122]. PXR also
plays a key role in chemotherapeutic resistance outcomes in specific cancers that include
breast, prostate, endometrial, ovarian, and colon cancers [116,122–128]. By regulating
the expression and activity of enzymes and proteins involved in drug metabolism, drug
transport, proliferation, apoptosis, anti-apoptosis, inflammation, and oxidative stress, PXR
activation in response to certain chemotherapeutics promotes the acquisition of resistance
to anti-cancer agents in a specific subset of tumors.
Taken together, these data indicate that PXR plays a differential role in regulating the
behavior of cancer cells, and the tumor type plays a very important role. It is clear that
additional research efforts are needed, and moving forward, investigators should likely focus
on the differential role of PXR biology, particularly in the context of disease states and various
pathophysiological conditions. It is worth stating here that “proper” or “normal” activation
of PXR in non-tumorigenic cells is likely to be very different from a mechanistic standpoint
when compared with “over/sub-activation” of PXR in diseased states. Future studies should
seek to unravel these mechanistic differences moving forward.
3.8. PXR-Target Gene Activation and Poly(ADP-Ribosyl)ation (PARylation)
The formation of poly(ADP-ribose) chains on the PXR protein likely functions to attract a
diverse set of PXR-accessory proteins. PARylation of PXR via PARP1 in response to xenobiotic
stress ultimately leads to chromatin remodeling. Additional studies have demonstrated
the role of poly(ADP-ribosyl)ation in the ubiquitin pathway. One such study published in
2016 demonstrated that PARylation may serve as a recognition signal for selected ubiquitin
ligases [99]. Further research is needed to unravel the precise role of PARylation in these
processes.
3.9. Summary
The interplay of acetylation, ubiquitylation, SUMOylation, and PARylation establishes
a likely temporal and spatial mechanism to drive the xenobiotic response. These interconnected signaling pathways frequently use positive feedback loops to amplify the signal and
further increase its specificity. It is currently unclear whether, or the extent to which, other
PTMs impact PXR biology when compared with other NRs to date. For example, O-linked
glycosylation and neddylation are known to affect the biology of other NR family members;
however, more research is needed to ascertain if PXR is the molecular target of these PTMs at
present. Indeed, much remains to be discovered regarding the precise molecular mechanisms
of how phosphorylation, SUMOylation, ubiquitylation, and acetylation signaling are intricately intertwined to help remove potentially toxic compounds from the human body. What
is clear is that phosphorylation-dependent mixed SUMO-ubiquitin chain formation on PXR
and its overall acetylation status all occur on Lys amino acid residues and have a particular
effect upon the metabolism and transport of xenobiotic compounds in the human body.
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